Beam Therapeutics Inc.
Beam Therapeutics Inc. (BEAM) Stock Competitors & Peer Comparison
See (BEAM) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BEAM | $31.58 | -0.54% | 3.2B | -64.45 | -$0.49 | N/A |
| VRTX | $448.29 | +3.01% | 113.8B | 26.60 | $16.85 | N/A |
| REGN | $723.41 | +1.49% | 74.5B | 17.66 | $40.96 | +0.50% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $812.81 | -0.06% | 50.3B | 36.06 | $22.54 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $292.03 | +2.52% | 39B | 73.16 | $3.99 | N/A |
| RVMD | $145.72 | +1.09% | 31B | -20.50 | -$7.11 | N/A |
| INSM | $116.00 | +11.66% | 25.1B | -20.14 | -$5.76 | N/A |
| UTHR | $581.74 | +2.08% | 24.7B | 21.50 | $27.06 | N/A |
Stock Comparison
BEAM vs VRTX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, VRTX has a market cap of 113.8B. Regarding current trading prices, BEAM is priced at $31.58, while VRTX trades at $448.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas VRTX's P/E ratio is 26.60. In terms of profitability, BEAM's ROE is -0.06%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, BEAM is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check VRTX's competition here
BEAM vs REGN Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, REGN has a market cap of 74.5B. Regarding current trading prices, BEAM is priced at $31.58, while REGN trades at $723.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas REGN's P/E ratio is 17.66. In terms of profitability, BEAM's ROE is -0.06%, compared to REGN's ROE of +0.14%. Regarding short-term risk, BEAM is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check REGN's competition here
BEAM vs VRNA Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, BEAM is priced at $31.58, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas VRNA's P/E ratio is -102.80. In terms of profitability, BEAM's ROE is -0.06%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, BEAM is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check VRNA's competition here
BEAM vs ARGX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, ARGX has a market cap of 50.3B. Regarding current trading prices, BEAM is priced at $31.58, while ARGX trades at $812.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas ARGX's P/E ratio is 36.06. In terms of profitability, BEAM's ROE is -0.06%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, BEAM is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check ARGX's competition here
BEAM vs SGEN Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, BEAM is priced at $31.58, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas SGEN's P/E ratio is -57.19. In terms of profitability, BEAM's ROE is -0.06%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, BEAM is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check SGEN's competition here
BEAM vs ALNY Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, ALNY has a market cap of 39B. Regarding current trading prices, BEAM is priced at $31.58, while ALNY trades at $292.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas ALNY's P/E ratio is 73.16. In terms of profitability, BEAM's ROE is -0.06%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, BEAM is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check ALNY's competition here
BEAM vs RVMD Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, RVMD has a market cap of 31B. Regarding current trading prices, BEAM is priced at $31.58, while RVMD trades at $145.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas RVMD's P/E ratio is -20.50. In terms of profitability, BEAM's ROE is -0.06%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, BEAM is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check RVMD's competition here
BEAM vs INSM Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, INSM has a market cap of 25.1B. Regarding current trading prices, BEAM is priced at $31.58, while INSM trades at $116.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas INSM's P/E ratio is -20.14. In terms of profitability, BEAM's ROE is -0.06%, compared to INSM's ROE of -1.30%. Regarding short-term risk, BEAM is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check INSM's competition here
BEAM vs UTHR Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, UTHR has a market cap of 24.7B. Regarding current trading prices, BEAM is priced at $31.58, while UTHR trades at $581.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas UTHR's P/E ratio is 21.50. In terms of profitability, BEAM's ROE is -0.06%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, BEAM is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check UTHR's competition here
BEAM vs BNTX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, BNTX has a market cap of 23.7B. Regarding current trading prices, BEAM is priced at $31.58, while BNTX trades at $93.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas BNTX's P/E ratio is -15.71. In terms of profitability, BEAM's ROE is -0.06%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, BEAM is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check BNTX's competition here
BEAM vs RPRX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, RPRX has a market cap of 22.2B. Regarding current trading prices, BEAM is priced at $31.58, while RPRX trades at $51.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas RPRX's P/E ratio is 27.21. In terms of profitability, BEAM's ROE is -0.06%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, BEAM is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check RPRX's competition here
BEAM vs MRNA Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, MRNA has a market cap of 21.1B. Regarding current trading prices, BEAM is priced at $31.58, while MRNA trades at $53.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas MRNA's P/E ratio is -6.54. In terms of profitability, BEAM's ROE is -0.06%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, BEAM is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check MRNA's competition here
BEAM vs ROIV Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, ROIV has a market cap of 21B. Regarding current trading prices, BEAM is priced at $31.58, while ROIV trades at $29.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas ROIV's P/E ratio is -25.12. In terms of profitability, BEAM's ROE is -0.06%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, BEAM is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check ROIV's competition here
BEAM vs BGNE Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, BEAM is priced at $31.58, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas BGNE's P/E ratio is -22.55. In terms of profitability, BEAM's ROE is -0.06%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, BEAM is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check BGNE's competition here
BEAM vs INCY Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, INCY has a market cap of 19.8B. Regarding current trading prices, BEAM is priced at $31.58, while INCY trades at $99.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas INCY's P/E ratio is 14.00. In terms of profitability, BEAM's ROE is -0.06%, compared to INCY's ROE of +0.29%. Regarding short-term risk, BEAM is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check INCY's competition here
BEAM vs DNA-WT Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, BEAM is priced at $31.58, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, BEAM's ROE is -0.06%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, BEAM is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check DNA-WT's competition here
BEAM vs GMAB Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, GMAB has a market cap of 16.6B. Regarding current trading prices, BEAM is priced at $31.58, while GMAB trades at $27.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas GMAB's P/E ratio is 20.52. In terms of profitability, BEAM's ROE is -0.06%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, BEAM is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check GMAB's competition here
BEAM vs SMMT Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, SMMT has a market cap of 14.7B. Regarding current trading prices, BEAM is priced at $31.58, while SMMT trades at $18.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas SMMT's P/E ratio is -11.92. In terms of profitability, BEAM's ROE is -0.06%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, BEAM is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check SMMT's competition here
BEAM vs ASND Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, BEAM is priced at $31.58, while ASND trades at $237.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas ASND's P/E ratio is 26.61. In terms of profitability, BEAM's ROE is -0.06%, compared to ASND's ROE of -56.42%. Regarding short-term risk, BEAM is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check ASND's competition here
BEAM vs JAZZ Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, JAZZ has a market cap of 14.3B. Regarding current trading prices, BEAM is priced at $31.58, while JAZZ trades at $227.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas JAZZ's P/E ratio is 2071.27. In terms of profitability, BEAM's ROE is -0.06%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, BEAM is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check JAZZ's competition here
BEAM vs BBIO Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, BBIO has a market cap of 12.9B. Regarding current trading prices, BEAM is priced at $31.58, while BBIO trades at $65.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas BBIO's P/E ratio is -17.63. In terms of profitability, BEAM's ROE is -0.06%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, BEAM is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check BBIO's competition here
BEAM vs KRTX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, BEAM is priced at $31.58, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas KRTX's P/E ratio is -28.09. In terms of profitability, BEAM's ROE is -0.06%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, BEAM is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check KRTX's competition here
BEAM vs IONS Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, IONS has a market cap of 12.5B. Regarding current trading prices, BEAM is priced at $31.58, while IONS trades at $75.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas IONS's P/E ratio is -37.73. In terms of profitability, BEAM's ROE is -0.06%, compared to IONS's ROE of -0.59%. Regarding short-term risk, BEAM is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check IONS's competition here
BEAM vs EXEL Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, EXEL has a market cap of 12.4B. Regarding current trading prices, BEAM is priced at $31.58, while EXEL trades at $49.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas EXEL's P/E ratio is 16.38. In terms of profitability, BEAM's ROE is -0.06%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, BEAM is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check EXEL's competition here
BEAM vs MDGL Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, BEAM is priced at $31.58, while MDGL trades at $510.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas MDGL's P/E ratio is -37.88. In terms of profitability, BEAM's ROE is -0.06%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, BEAM is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check MDGL's competition here
BEAM vs AXSM Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, AXSM has a market cap of 11.5B. Regarding current trading prices, BEAM is priced at $31.58, while AXSM trades at $224.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas AXSM's P/E ratio is -60.18. In terms of profitability, BEAM's ROE is -0.06%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, BEAM is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check AXSM's competition here
BEAM vs RNAM Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, BEAM is priced at $31.58, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas RNAM's P/E ratio is -17.39. In terms of profitability, BEAM's ROE is -0.06%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, BEAM is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check RNAM's competition here
BEAM vs ARWR Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, ARWR has a market cap of 11.1B. Regarding current trading prices, BEAM is priced at $31.58, while ARWR trades at $79.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas ARWR's P/E ratio is -34.82. In terms of profitability, BEAM's ROE is -0.06%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, BEAM is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check ARWR's competition here
BEAM vs BMRN Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, BMRN has a market cap of 10.2B. Regarding current trading prices, BEAM is priced at $31.58, while BMRN trades at $52.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas BMRN's P/E ratio is 38.04. In terms of profitability, BEAM's ROE is -0.06%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, BEAM is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check BMRN's competition here
BEAM vs RXDX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, BEAM is priced at $31.58, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas RXDX's P/E ratio is -56.47. In terms of profitability, BEAM's ROE is -0.06%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, BEAM is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check RXDX's competition here
BEAM vs CYTK Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, CYTK has a market cap of 9.3B. Regarding current trading prices, BEAM is priced at $31.58, while CYTK trades at $74.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas CYTK's P/E ratio is -10.92. In terms of profitability, BEAM's ROE is -0.06%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, BEAM is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check CYTK's competition here
BEAM vs KRYS Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, KRYS has a market cap of 9.1B. Regarding current trading prices, BEAM is priced at $31.58, while KRYS trades at $310.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas KRYS's P/E ratio is 41.49. In terms of profitability, BEAM's ROE is -0.06%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, BEAM is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check KRYS's competition here
BEAM vs IMGN Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, BEAM is priced at $31.58, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas IMGN's P/E ratio is -111.55. In terms of profitability, BEAM's ROE is -0.06%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, BEAM is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check IMGN's competition here
BEAM vs IBRX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, BEAM is priced at $31.58, while IBRX trades at $8.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas IBRX's P/E ratio is -10.02. In terms of profitability, BEAM's ROE is -0.06%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, BEAM is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check IBRX's competition here
BEAM vs HALO Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, HALO has a market cap of 8.4B. Regarding current trading prices, BEAM is priced at $31.58, while HALO trades at $70.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas HALO's P/E ratio is 27.71. In terms of profitability, BEAM's ROE is -0.06%, compared to HALO's ROE of +1.26%. Regarding short-term risk, BEAM is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check HALO's competition here
BEAM vs BPMC Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, BEAM is priced at $31.58, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas BPMC's P/E ratio is -51.58. In terms of profitability, BEAM's ROE is -0.06%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, BEAM is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check BPMC's competition here
BEAM vs CERE Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, BEAM is priced at $31.58, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas CERE's P/E ratio is -16.47. In terms of profitability, BEAM's ROE is -0.06%, compared to CERE's ROE of -0.72%. Regarding short-term risk, BEAM is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check CERE's competition here
BEAM vs ABVX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, BEAM is priced at $31.58, while ABVX trades at $121.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas ABVX's P/E ratio is -21.43. In terms of profitability, BEAM's ROE is -0.06%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, BEAM is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check ABVX's competition here
BEAM vs PCVX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, BEAM is priced at $31.58, while PCVX trades at $54.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas PCVX's P/E ratio is -7.84. In terms of profitability, BEAM's ROE is -0.06%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, BEAM is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check PCVX's competition here
BEAM vs NUVL Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, NUVL has a market cap of 7.5B. Regarding current trading prices, BEAM is priced at $31.58, while NUVL trades at $102.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas NUVL's P/E ratio is -16.92. In terms of profitability, BEAM's ROE is -0.06%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, BEAM is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check NUVL's competition here
BEAM vs MTSR Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, BEAM is priced at $31.58, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas MTSR's P/E ratio is -23.58. In terms of profitability, BEAM's ROE is -0.06%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, BEAM is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check MTSR's competition here
BEAM vs TECH Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, TECH has a market cap of 7.4B. Regarding current trading prices, BEAM is priced at $31.58, while TECH trades at $47.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas TECH's P/E ratio is 67.74. In terms of profitability, BEAM's ROE is -0.06%, compared to TECH's ROE of +0.05%. Regarding short-term risk, BEAM is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check TECH's competition here
BEAM vs PRAX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, PRAX has a market cap of 7.3B. Regarding current trading prices, BEAM is priced at $31.58, while PRAX trades at $343.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas PRAX's P/E ratio is -25.65. In terms of profitability, BEAM's ROE is -0.06%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, BEAM is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check PRAX's competition here
BEAM vs KYMR Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, KYMR has a market cap of 6.9B. Regarding current trading prices, BEAM is priced at $31.58, while KYMR trades at $83.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas KYMR's P/E ratio is -23.34. In terms of profitability, BEAM's ROE is -0.06%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, BEAM is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check KYMR's competition here
BEAM vs MRUS Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, BEAM is priced at $31.58, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas MRUS's P/E ratio is -17.05. In terms of profitability, BEAM's ROE is -0.06%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, BEAM is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check MRUS's competition here
BEAM vs ACLX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, BEAM is priced at $31.58, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas ACLX's P/E ratio is -28.27. In terms of profitability, BEAM's ROE is -0.06%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, BEAM is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check ACLX's competition here
BEAM vs RETA Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, BEAM is priced at $31.58, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas RETA's P/E ratio is -66.29. In terms of profitability, BEAM's ROE is -0.06%, compared to RETA's ROE of +0.47%. Regarding short-term risk, BEAM is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check RETA's competition here
BEAM vs TGTX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, TGTX has a market cap of 6.5B. Regarding current trading prices, BEAM is priced at $31.58, while TGTX trades at $42.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas TGTX's P/E ratio is 14.87. In terms of profitability, BEAM's ROE is -0.06%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, BEAM is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check TGTX's competition here
BEAM vs PTGX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, PTGX has a market cap of 6.4B. Regarding current trading prices, BEAM is priced at $31.58, while PTGX trades at $99.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas PTGX's P/E ratio is -55.22. In terms of profitability, BEAM's ROE is -0.06%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, BEAM is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check PTGX's competition here
BEAM vs ALKS Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, ALKS has a market cap of 6.4B. Regarding current trading prices, BEAM is priced at $31.58, while ALKS trades at $38.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas ALKS's P/E ratio is 42.54. In terms of profitability, BEAM's ROE is -0.06%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, BEAM is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check ALKS's competition here
BEAM vs RYTM Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, RYTM has a market cap of 6.3B. Regarding current trading prices, BEAM is priced at $31.58, while RYTM trades at $91.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas RYTM's P/E ratio is -29.17. In terms of profitability, BEAM's ROE is -0.06%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, BEAM is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check RYTM's competition here
BEAM vs PTCT Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, PTCT has a market cap of 6.2B. Regarding current trading prices, BEAM is priced at $31.58, while PTCT trades at $75.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas PTCT's P/E ratio is -29.54. In terms of profitability, BEAM's ROE is -0.06%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, BEAM is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check PTCT's competition here
BEAM vs BLTE Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, BEAM is priced at $31.58, while BLTE trades at $155.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas BLTE's P/E ratio is -67.63. In terms of profitability, BEAM's ROE is -0.06%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, BEAM is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check BLTE's competition here
BEAM vs CNTA Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, BEAM is priced at $31.58, while CNTA trades at $39.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas CNTA's P/E ratio is -22.25. In terms of profitability, BEAM's ROE is -0.06%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, BEAM is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check CNTA's competition here
BEAM vs CGON Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, CGON has a market cap of 6.1B. Regarding current trading prices, BEAM is priced at $31.58, while CGON trades at $72.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas CGON's P/E ratio is -30.80. In terms of profitability, BEAM's ROE is -0.06%, compared to CGON's ROE of -0.23%. Regarding short-term risk, BEAM is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check CGON's competition here
BEAM vs CELC Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, CELC has a market cap of 6B. Regarding current trading prices, BEAM is priced at $31.58, while CELC trades at $124.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas CELC's P/E ratio is -32.90. In terms of profitability, BEAM's ROE is -0.06%, compared to CELC's ROE of -2.03%. Regarding short-term risk, BEAM is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check CELC's competition here
BEAM vs COGT Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, BEAM is priced at $31.58, while COGT trades at $34.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas COGT's P/E ratio is -15.91. In terms of profitability, BEAM's ROE is -0.06%, compared to COGT's ROE of -0.83%. Regarding short-term risk, BEAM is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check COGT's competition here
BEAM vs SRRK Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, BEAM is priced at $31.58, while SRRK trades at $49.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas SRRK's P/E ratio is -14.26. In terms of profitability, BEAM's ROE is -0.06%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, BEAM is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check SRRK's competition here
BEAM vs IMVT Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, IMVT has a market cap of 5.8B. Regarding current trading prices, BEAM is priced at $31.58, while IMVT trades at $28.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas IMVT's P/E ratio is -10.73. In terms of profitability, BEAM's ROE is -0.06%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, BEAM is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check IMVT's competition here
BEAM vs CDTX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, BEAM is priced at $31.58, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas CDTX's P/E ratio is -19.77. In terms of profitability, BEAM's ROE is -0.06%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, BEAM is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check CDTX's competition here
BEAM vs ABCM Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, BEAM is priced at $31.58, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, BEAM's ROE is -0.06%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, BEAM is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check ABCM's competition here
BEAM vs ISEE Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, BEAM is priced at $31.58, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas ISEE's P/E ratio is -22.44. In terms of profitability, BEAM's ROE is -0.06%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, BEAM is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check ISEE's competition here
BEAM vs CORT Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, CORT has a market cap of 5.5B. Regarding current trading prices, BEAM is priced at $31.58, while CORT trades at $51.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas CORT's P/E ratio is 146.17. In terms of profitability, BEAM's ROE is -0.06%, compared to CORT's ROE of +0.08%. Regarding short-term risk, BEAM is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check CORT's competition here
BEAM vs MIRM Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, MIRM has a market cap of 5.4B. Regarding current trading prices, BEAM is priced at $31.58, while MIRM trades at $106.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas MIRM's P/E ratio is -7.86. In terms of profitability, BEAM's ROE is -0.06%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, BEAM is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check MIRM's competition here
BEAM vs APLS Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, BEAM is priced at $31.58, while APLS trades at $41.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas APLS's P/E ratio is 38.37. In terms of profitability, BEAM's ROE is -0.06%, compared to APLS's ROE of +0.40%. Regarding short-term risk, BEAM is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check APLS's competition here
BEAM vs LEGN Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, LEGN has a market cap of 5.2B. Regarding current trading prices, BEAM is priced at $31.58, while LEGN trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas LEGN's P/E ratio is -17.44. In terms of profitability, BEAM's ROE is -0.06%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, BEAM is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check LEGN's competition here
BEAM vs FBIOX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, BEAM is priced at $31.58, while FBIOX trades at $25.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas FBIOX's P/E ratio is N/A. In terms of profitability, BEAM's ROE is -0.06%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, BEAM is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check FBIOX's competition here
BEAM vs APGE Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, BEAM is priced at $31.58, while APGE trades at $82.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas APGE's P/E ratio is -19.15. In terms of profitability, BEAM's ROE is -0.06%, compared to APGE's ROE of -0.24%. Regarding short-term risk, BEAM is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check APGE's competition here
BEAM vs CRSP Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, BEAM is priced at $31.58, while CRSP trades at $52.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas CRSP's P/E ratio is -8.56. In terms of profitability, BEAM's ROE is -0.06%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, BEAM is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check CRSP's competition here
BEAM vs LQDA Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, LQDA has a market cap of 5B. Regarding current trading prices, BEAM is priced at $31.58, while LQDA trades at $56.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas LQDA's P/E ratio is 332.94. In terms of profitability, BEAM's ROE is -0.06%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, BEAM is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check LQDA's competition here
BEAM vs TERN Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, BEAM is priced at $31.58, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas TERN's P/E ratio is -51.41. In terms of profitability, BEAM's ROE is -0.06%, compared to TERN's ROE of -0.20%. Regarding short-term risk, BEAM is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check TERN's competition here
BEAM vs CAI Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, BEAM is priced at $31.58, while CAI trades at $16.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas CAI's P/E ratio is -5.94. In terms of profitability, BEAM's ROE is -0.06%, compared to CAI's ROE of +0.06%. Regarding short-term risk, BEAM is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check CAI's competition here
BEAM vs FOLD Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, BEAM is priced at $31.58, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas FOLD's P/E ratio is -161.00. In terms of profitability, BEAM's ROE is -0.06%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, BEAM is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check FOLD's competition here
BEAM vs NAMS Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, NAMS has a market cap of 4.5B. Regarding current trading prices, BEAM is priced at $31.58, while NAMS trades at $38.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas NAMS's P/E ratio is -21.85. In terms of profitability, BEAM's ROE is -0.06%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, BEAM is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check NAMS's competition here
BEAM vs SYRE Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, SYRE has a market cap of 4.5B. Regarding current trading prices, BEAM is priced at $31.58, while SYRE trades at $75.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas SYRE's P/E ratio is -35.40. In terms of profitability, BEAM's ROE is -0.06%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, BEAM is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check SYRE's competition here
BEAM vs AKRO Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, BEAM is priced at $31.58, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas AKRO's P/E ratio is -14.57. In terms of profitability, BEAM's ROE is -0.06%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, BEAM is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check AKRO's competition here
BEAM vs KNSA Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, KNSA has a market cap of 4.5B. Regarding current trading prices, BEAM is priced at $31.58, while KNSA trades at $59.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas KNSA's P/E ratio is 65.36. In terms of profitability, BEAM's ROE is -0.06%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, BEAM is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check KNSA's competition here
BEAM vs ALPN Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, BEAM is priced at $31.58, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas ALPN's P/E ratio is -101.52. In terms of profitability, BEAM's ROE is -0.06%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, BEAM is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check ALPN's competition here
BEAM vs LGND Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, LGND has a market cap of 4.4B. Regarding current trading prices, BEAM is priced at $31.58, while LGND trades at $222.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas LGND's P/E ratio is 28.91. In terms of profitability, BEAM's ROE is -0.06%, compared to LGND's ROE of +0.16%. Regarding short-term risk, BEAM is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check LGND's competition here
BEAM vs XENE Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, BEAM is priced at $31.58, while XENE trades at $55.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas XENE's P/E ratio is -11.70. In terms of profitability, BEAM's ROE is -0.06%, compared to XENE's ROE of -0.49%. Regarding short-term risk, BEAM is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check XENE's competition here
BEAM vs MANE Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, BEAM is priced at $31.58, while MANE trades at $103.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas MANE's P/E ratio is -43.66. In terms of profitability, BEAM's ROE is -0.06%, compared to MANE's ROE of -0.76%. Regarding short-term risk, BEAM is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check MANE's competition here
BEAM vs OPT Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, BEAM is priced at $31.58, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas OPT's P/E ratio is -1.52. In terms of profitability, BEAM's ROE is -0.06%, compared to OPT's ROE of +0.88%. Regarding short-term risk, BEAM is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check OPT's competition here
BEAM vs MRTX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, BEAM is priced at $31.58, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas MRTX's P/E ratio is -4.82. In terms of profitability, BEAM's ROE is -0.06%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, BEAM is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check MRTX's competition here
BEAM vs TVTX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, TVTX has a market cap of 4B. Regarding current trading prices, BEAM is priced at $31.58, while TVTX trades at $42.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas TVTX's P/E ratio is -85.68. In terms of profitability, BEAM's ROE is -0.06%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, BEAM is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check TVTX's competition here
BEAM vs CRNX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, BEAM is priced at $31.58, while CRNX trades at $36.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas CRNX's P/E ratio is -7.18. In terms of profitability, BEAM's ROE is -0.06%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, BEAM is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check CRNX's competition here
BEAM vs CPRX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, BEAM is priced at $31.58, while CPRX trades at $31.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas CPRX's P/E ratio is 18.54. In terms of profitability, BEAM's ROE is -0.06%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, BEAM is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check CPRX's competition here
BEAM vs RYZB Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, BEAM is priced at $31.58, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas RYZB's P/E ratio is -57.86. In terms of profitability, BEAM's ROE is -0.06%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, BEAM is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check RYZB's competition here
BEAM vs CBAY Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, BEAM is priced at $31.58, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas CBAY's P/E ratio is -32.81. In terms of profitability, BEAM's ROE is -0.06%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, BEAM is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check CBAY's competition here
BEAM vs ACAD Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, BEAM is priced at $31.58, while ACAD trades at $21.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas ACAD's P/E ratio is 9.82. In terms of profitability, BEAM's ROE is -0.06%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, BEAM is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check ACAD's competition here
BEAM vs EWTX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, EWTX has a market cap of 3.7B. Regarding current trading prices, BEAM is priced at $31.58, while EWTX trades at $34.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas EWTX's P/E ratio is -20.49. In terms of profitability, BEAM's ROE is -0.06%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, BEAM is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check EWTX's competition here
BEAM vs VKTX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, BEAM is priced at $31.58, while VKTX trades at $31.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas VKTX's P/E ratio is -7.55. In terms of profitability, BEAM's ROE is -0.06%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, BEAM is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check VKTX's competition here
BEAM vs DNTH Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, BEAM is priced at $31.58, while DNTH trades at $86.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas DNTH's P/E ratio is -20.37. In terms of profitability, BEAM's ROE is -0.06%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, BEAM is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check DNTH's competition here
BEAM vs SWTX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, BEAM is priced at $31.58, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas SWTX's P/E ratio is -13.78. In terms of profitability, BEAM's ROE is -0.06%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, BEAM is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check SWTX's competition here
BEAM vs TLX Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, BEAM is priced at $31.58, while TLX trades at $10.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas TLX's P/E ratio is -519.50. In terms of profitability, BEAM's ROE is -0.06%, compared to TLX's ROE of -0.02%. Regarding short-term risk, BEAM is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check TLX's competition here
BEAM vs ERAS Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, ERAS has a market cap of 3.2B. Regarding current trading prices, BEAM is priced at $31.58, while ERAS trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas ERAS's P/E ratio is -23.59. In terms of profitability, BEAM's ROE is -0.06%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, BEAM is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check ERAS's competition here
BEAM vs VCYT Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, VCYT has a market cap of 3.2B. Regarding current trading prices, BEAM is priced at $31.58, while VCYT trades at $39.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas VCYT's P/E ratio is 36.63. In terms of profitability, BEAM's ROE is -0.06%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, BEAM is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check VCYT's competition here
BEAM vs NAMSW Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, NAMSW has a market cap of 3.1B. Regarding current trading prices, BEAM is priced at $31.58, while NAMSW trades at $27.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas NAMSW's P/E ratio is N/A. In terms of profitability, BEAM's ROE is -0.06%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, BEAM is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for BEAM.Check NAMSW's competition here
BEAM vs DNLI Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, BEAM is priced at $31.58, while DNLI trades at $19.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas DNLI's P/E ratio is -6.76. In terms of profitability, BEAM's ROE is -0.06%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, BEAM is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check DNLI's competition here
BEAM vs DYN Comparison May 2026
BEAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BEAM stands at 3.2B. In comparison, DYN has a market cap of 3B. Regarding current trading prices, BEAM is priced at $31.58, while DYN trades at $18.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BEAM currently has a P/E ratio of -64.45, whereas DYN's P/E ratio is -5.83. In terms of profitability, BEAM's ROE is -0.06%, compared to DYN's ROE of -0.58%. Regarding short-term risk, BEAM is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for BEAM.Check DYN's competition here